tetrahydrozoline/zinc sulfate/hypromellose ophthalmic (Rohto Ice, Rohto Relief)

Dosing and uses of Rohto Ice, Rohto Relief (tetrahydrozoline/zinc sulfate/hypromellose ophthalmic)

• Adult
• Pediatric

 

Adult dosage forms and strengths

tetrahydrozoline/zinc sulfate/hypromellose

ophthalmic solution

• 0.05%/0.25%/0.2%

 

Ocular Redness & Irritation

Indicated to temporarily relieve discomfort due to minor ophthalmic irritations and redness

1-2 gtt in each eye PRN; not to exceed 4 doses/day

 

Administration

Do not touch tip of container to any surface to avoid contamination

Replace cap after each use

Do not use if solution changes color or becomes cloudy

Remove contact lenses before use

 

Pediatric dosage forms and strengths

tetrahydrozoline/zinc sulfate/hypromellose

ophthalmic solution

• 0.05%/0.25%/0.2%

 

Ocular Redness & Irritation

Indicated to temporarily relieve discomfort due to minor ophthalmic irritations and redness

1-2 gtt in each eye PRN; not to exceed 4 doses/day

 

Administration

Do not touch tip of container to any surface to avoid contamination

Replace cap after each use

Do not use if solution changes color or becomes cloudy

Remove contact lenses before use

 

Rohto Ice, Rohto Relief (tetrahydrozoline/zinc sulfate/hypromellose ophthalmic) adverse (side) effects

Frequency not defined

Increased IOp

Transient blurred vision

Transient ocular dryness

Transient ocular burning/stinging

Rebound conjunctival hyperemia

 

Warnings

Contraindications

Hypersensitivity

 

Cautions

Discontinue use if the following occurs

• Eye pain
• Vision changes
• Unresolved redness or irritation
• Condition worsens or lasts >72 hr

Tetrahydrozoline

• Narrow angle glaucoma
• May cause temporary mydriasis
• Use caution in hypertension, coronary artery disease, diabetes, and hyperthyroidism

 

Pregnancy and lactation

Pregnancy category: B

Lactation: Unknown if distributed in human breast milk

Pregnant or breastfeeding patients should seek advice of health professional before using OTC drugs

 

Pregnancy categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

 

Pharmacology of Rohto Ice, Rohto Relief (tetrahydrozoline/zinc sulfate/hypromellose ophthalmic)

Mechanism of action

Tetrahydrozoline: Ophthalmic decongestant; reduces redness; stimulates alpha-adrenergic receptors in the arterioles of the conjunctiva; produces vasoconstriction; may produce mydriasis when applied to the conjunctiva, but this effect is usually minimal with the concentrations used as ocular decongestants

Zinc sulfate: Provides astringent effects to dry mucus and relieve irritation

Hypromellose: Demulcent that lubricates eye surface